Innovative Companies Diving into The Neuro Market Ahead of 2021
The Pharma Data
DECEMBER 9, 2020
Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., Vigil’s $50 million Series A financing, completed this week, was powered by Atlas Ventures and Northpond Ventures, and includes participating investors Hatteras Partners and Alexandria Venture Investments. SciNeuro Pharmaceuticals.
Let's personalize your content